<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666796</url>
  </required_header>
  <id_info>
    <org_study_id>A9451149</org_study_id>
    <nct_id>NCT00666796</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, 4-Way Crossover, Placebo-Controlled, Single Center Trial to Evaluate the Potential Pharmacodynamic Interaction Between Gabapentin 500 mg and Ethanol in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamic interaction between gabapentin and
      ethanol
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from pre-dose in the Psychomotor Vigilance Task (PVT) for completed subjects</measure>
    <time_frame>2 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in DSST for Intent-to-Treat (ITTI subjects</measure>
    <time_frame>2 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in PVT for ITT subjects</measure>
    <time_frame>2 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in Buschke Selective Reminding Test (BSRT) for completed subjects</measure>
    <time_frame>2 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in BSRT for ITT subjects</measure>
    <time_frame>2 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in Stanford Sleepiness Scale (SSS) for completed subjects</measure>
    <time_frame>2, 6, and 7.5 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in SSS for ITT subjects</measure>
    <time_frame>2, 6, and 7.5 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Throughout study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in PVT for completed subjects</measure>
    <time_frame>6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose in Digit Symbol Substitution Test (DSST) for completed subjects</measure>
    <time_frame>2 and 6 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ethanol</intervention_name>
    <description>Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ethanol</intervention_name>
    <description>Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers in good health aged 21 to 50 (inclusive) years who weigh 50 to 100 kg
             (110-220 lbs.)

          -  Experience with alcohol, defined as mild to moderate use of alcohol, ie, maximum of 14
             alcoholic drinks per week

        Exclusion Criteria:

          -  Recent history (within 2 years) of, or current treatment for, a sleeping disorder
             including excessive snoring, obstructive sleep apnea or a chronic painful condition

          -  Recent history (within 2 years) of, or clinical evidence of significant unstable or
             uncontrolled respiratory (including asthma and congestive obstructive pulmonary
             disease), cardiovascular, gastrointestinal, hepatic, renal, endocrine, neurologic
             (including seizures), psychiatric or other chronic disease

          -  History of alcoholism or drug abuse; recreational drug use within the past 30 days;
             use of benzodiazepines, Ambien®, Sonata®, antidepressants or psychoactive medication
             within 30 days prior to screening; use of any other sedative, hypnotic, antihistamine,
             anticholinergic, melatonin, DHEA or herbal sleep/relaxation remedy within 7 days prior
             to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451149&amp;StudyName=A%20Study%20to%20Assess%20the%20Pharmacodynamic%20Interaction%20between%20Gabapentin%20and%20Ethanol%20in%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

